D
Viridian Therapeutics, Inc.
VRDN
$12.02
$0.615.35%
D
Sell
12/18/2023Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index.
E
Sell
11/14/2023Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 11/14/2023 due to a noticeable decline in the growth index, total return index and solvency index. Debt to equity increased from 0.03 to 0.14.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 11/14/2023 due to a noticeable decline in the growth index, total return index and solvency index. Debt to equity increased from 0.03 to 0.14.
D
Sell
10/2/2023Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D- from E+ on 10/2/2023 due to a large increase in the growth index and valuation index. Operating cash flow increased 27.04% from -$61.97M to -$45.21M, earnings per share increased from -$1.6133 to -$1.273, and EBIT increased 18.21% from -$72.47M to -$59.28M.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D- from E+ on 10/2/2023 due to a large increase in the growth index and valuation index. Operating cash flow increased 27.04% from -$61.97M to -$45.21M, earnings per share increased from -$1.6133 to -$1.273, and EBIT increased 18.21% from -$72.47M to -$59.28M.
E
Sell
7/27/2023Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 7/27/2023 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 82.05% from -$34.04M to -$61.97M, EBIT declined 47.71% from -$49.07M to -$72.47M, and earnings per share declined from -$1.1293 to -$1.6133.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 7/27/2023 due to a significant decline in the total return index, volatility index and growth index. Operating cash flow declined 82.05% from -$34.04M to -$61.97M, EBIT declined 47.71% from -$49.07M to -$72.47M, and earnings per share declined from -$1.1293 to -$1.6133.
D
Sell
3/14/2023Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Total revenue declined 91.21% from $1.2M to $105, EBIT declined 64.73% from -$29.79M to -$49.07M, and operating cash flow declined 64.71% from -$20.67M to -$34.04M.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Total revenue declined 91.21% from $1.2M to $105, EBIT declined 64.73% from -$29.79M to -$49.07M, and operating cash flow declined 64.71% from -$20.67M to -$34.04M.
D
Sell
2/23/2023Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and total return index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and total return index.
D
Sell
12/2/2022Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D from D+ on 12/2/2022 due to a decline in the valuation index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D from D+ on 12/2/2022 due to a decline in the valuation index.
D
Sell
11/15/2022Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D+ from D on 11/15/2022 due to a significant increase in the total return index, volatility index and valuation index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D+ from D on 11/15/2022 due to a significant increase in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$1.3092 to -$0.9834, EBIT increased 10.98% from -$29.08M to -$25.89M, and total revenue increased 0.93% from $214 to $216.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$1.3092 to -$0.9834, EBIT increased 10.98% from -$29.08M to -$25.89M, and total revenue increased 0.93% from $214 to $216.
E
Sell
5/13/2022Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 05/04/2022.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/20/2022Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
11/9/2021Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/3/2021Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index.
D
Sell
10/19/2021Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 10/19/2021 due to a decline in the volatility index and total return index.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 10/19/2021 due to a decline in the volatility index and total return index.
D
Sell
10/4/2021Upgraded
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 10/4/2021 due to an increase in the volatility index.
Viridian Therapeutics, Inc. (VRDN) was upgraded to D from D- on 10/4/2021 due to an increase in the volatility index.
D
Sell
8/31/2021Downgrade
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 8/31/2021 due to a major decline in the growth index and solvency index. Operating cash flow declined 26.8% from -$11.54M to -$14.63M, total revenue declined 24.88% from $1.45M to $1.09M, and the quick ratio declined from 7.21 to 6.62.
Viridian Therapeutics, Inc. (VRDN) was downgraded to D- from D on 8/31/2021 due to a major decline in the growth index and solvency index. Operating cash flow declined 26.8% from -$11.54M to -$14.63M, total revenue declined 24.88% from $1.45M to $1.09M, and the quick ratio declined from 7.21 to 6.62.
D
Sell
5/1/2020Upgraded
Miragen Therapeutics (MGEN) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, solvency index and growth index.
Miragen Therapeutics (MGEN) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, solvency index and growth index.
D
Sell
3/16/2020Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 3/16/2020 due to a major increase in the growth index. Total revenue increased 26.62% from $695 to $880, operating cash flow increased 15.77% from -$9.27M to -$7.81M, and earnings per share increased from -$0.3613 to -$0.3125.
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 3/16/2020 due to a major increase in the growth index. Total revenue increased 26.62% from $695 to $880, operating cash flow increased 15.77% from -$9.27M to -$7.81M, and earnings per share increased from -$0.3613 to -$0.3125.
E
Sell
2/28/2020Downgrade
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 2/28/2020 due to a decline in the volatility index.
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 2/28/2020 due to a decline in the volatility index.
D
Sell
2/12/2020Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index.
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index.
E
Sell
9/30/2019Downgrade
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 9/30/2019 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 7.48 to 4.95, and debt to equity increased from 0.25 to 0.3.
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 9/30/2019 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 7.48 to 4.95, and debt to equity increased from 0.25 to 0.3.
D
Sell
7/10/2019Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 7/10/2019 due to an increase in the volatility index and valuation index.
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E+ on 7/10/2019 due to an increase in the volatility index and valuation index.
E
Sell
6/24/2019Downgrade
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 6/24/2019 due to a substantial decline in the solvency index, growth index and volatility index. Operating cash flow declined 44.45% from -$8.18M to -$11.81M, debt to equity increased from 0.2 to 0.25, and total revenue declined 21.85% from $476 to $372.
miRagen Therapeutics, Inc. (MGEN) was downgraded to E+ from D- on 6/24/2019 due to a substantial decline in the solvency index, growth index and volatility index. Operating cash flow declined 44.45% from -$8.18M to -$11.81M, debt to equity increased from 0.2 to 0.25, and total revenue declined 21.85% from $476 to $372.
D
Sell
11/8/2018Downgrade
miRagen Therapeutics, Inc. (MGEN) was downgraded to D- from D on 11/8/2018 due to a noticeable decline in the growth index, efficiency index and total return index. Total revenue declined 56.74% from $2.18M to $944, operating cash flow declined 50.95% from -$4.51M to -$6.8M, and total capital declined 8.82% from $77.78M to $70.92M.
miRagen Therapeutics, Inc. (MGEN) was downgraded to D- from D on 11/8/2018 due to a noticeable decline in the growth index, efficiency index and total return index. Total revenue declined 56.74% from $2.18M to $944, operating cash flow declined 50.95% from -$4.51M to -$6.8M, and total capital declined 8.82% from $77.78M to $70.92M.
D
Sell
5/10/2018Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to D from D- on 5/10/2018 due to a noticeable increase in the growth index, valuation index and efficiency index. Total revenue increased 301.34% from $1.19M to $4.78M, total capital increased 70.8% from $48.43M to $82.72M, and earnings per share increased from -$0.2864 to -$0.18.
miRagen Therapeutics, Inc. (MGEN) was upgraded to D from D- on 5/10/2018 due to a noticeable increase in the growth index, valuation index and efficiency index. Total revenue increased 301.34% from $1.19M to $4.78M, total capital increased 70.8% from $48.43M to $82.72M, and earnings per share increased from -$0.2864 to -$0.18.
D
Sell
11/1/2017Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E on 11/1/2017 due to an increase in the valuation index and growth index. Total revenue increased 55.41% from $462 to $718, earnings per share increased from -$0.6045 to -$0.3415, and operating cash flow increased 13.5% from -$8.18M to -$7.08M.
miRagen Therapeutics, Inc. (MGEN) was upgraded to D- from E on 11/1/2017 due to an increase in the valuation index and growth index. Total revenue increased 55.41% from $462 to $718, earnings per share increased from -$0.6045 to -$0.3415, and operating cash flow increased 13.5% from -$8.18M to -$7.08M.
E
Sell
8/1/2017Upgraded
miRagen Therapeutics, Inc. (MGEN) was upgraded to E from E- on 8/1/2017 due to a large increase in the solvency index and volatility index.
miRagen Therapeutics, Inc. (MGEN) was upgraded to E from E- on 8/1/2017 due to a large increase in the solvency index and volatility index.
E
Sell
5/24/2017None
Viridian Therapeutics, Inc. (VRDN) was downgraded to E- from U on 05/24/2017.
Viridian Therapeutics, Inc. (VRDN) was downgraded to E- from U on 05/24/2017.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
